ClinicalTrials.gg
RecruitingNCT06865105Updated Nov 9, 2026

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

A Phase 2 interventional study of Lutikizumab and Risankizumab in Psoriatic Arthritis, sponsored by AbbVie. Recruiting at 41 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Nov 9, 2026Site recruiting status changedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Planned enrollment
5th of 11
300 · median 246
Started
2025
with 1 other
Phase 2
5 of 34
1 open now
Registered
34th of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 2, and was the 34th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms.

The therapies being assessed in this study are risankizumab, lutikizumab, ABBV-701, and ABBV-547. In Substudy 1, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. In Substudy 2, participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: ABBV-701 monotherapy, risankizumab monotherapy, or a combination therapy of ABBV-701 and risankizumab. In Substudy 3, participants will be randomized in a 1:1:1 ratio to one of three doses of ABBV-547. Around 300 participants will be enrolled in the study at approximately 110 sites worldwide.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • Psoriatic Arthritis
  • Risankizumab
  • Lutikizumab
  • ABBV-701
  • ABBV-547
  • Appaloosa
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
  • Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
  • Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
  • Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
  • Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion criteria

Exclusion Criteria:

  • Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
  • Participants with the following active, chronic, or recurring infections: Are infected with (HIV), active virus (HBV) or virus(HCV) infection, active tuberculosis(TB)
  • Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
  • History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Substudy 1: Risankizumab Monotherapy

    Participants will receive risankizumab

    Drug: Risankizumab

  • Experimental
    Substudy 1: Lutikizumab Monotherapy

    Participants will initially receive lutikizumab Dose A followed by Lutikizumab Dose B every other week.

    Drug: Lutikizumab

  • Experimental
    Substudy 1: Lutikizumab and Risankizumab Combination Therapy

    Participants will be administered lutikizumab and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

    Drug: Lutikizumab · Drug: Risankizumab

  • Experimental
    Substudy 2: ABBV-701 Monotherapy

    Participants will initially receive ABBV-701.

    Drug: ABBV-701

  • Experimental
    Substudy 2: Risankizumab Monotherapy

    Participants will receive risankizumab.

    Drug: Risankizumab

  • Experimental
    Substudy 2: ABBV-701 and Risankizumab Combination Therapy

    Participants will be administered ABBV-701 and risankizumab at the same time following the same dosing regimen as the monotherapy arms.

    Drug: Risankizumab · Drug: ABBV-701

  • Experimental
    Substudy 3: ABBV-547 Dose A

    Participants will receive ABBV-547 Dose A.

    Drug: ABBV-547

  • Experimental
    Substudy 3: ABBV-547 Dose B

    Participants will receive ABBV-547 Dose B.

    Drug: ABBV-547

  • Experimental
    Substudy 3: ABBV-547 Dose C

    Participants will receive ABBV-547 Dose C.

    Drug: ABBV-547

Interventions

  • Subcutaneous (SC) Injection

  • Subcutaneous (SC) Injection

  • Subcutaneous (SC) Injection

  • DrugABBV-547

    Subcutaneous (SC) Injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria: 1. ≥ 50% improvement in 68-tender joint count; 2. ≥ 50% improvement in 66-swollen joint count; and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: At Week 16

  2. Number of Participants With Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Minimal Disease Activity (MDA) Response

    A participant was classified as achieving MDA if 5 of the following 7 criteria were met: * Tender joint count (out of 68 joints) ≤ 1 * Swollen joint count (out of 66 joints) ≤ 1 * PASI score ≤ 1 (score ranges from 0 - 72) or percent BSA involved with psoriasis ≤ 3% * Participant's assessment of pain ≤ 1.5 (NRS from 0 to 10) * Participant's Global Assessment of disease activity ≤ 2 (NRS from 0 to 10) * HAQ-DI score ≤ 0.5 (index score ranges from 0 to 3) * Leeds Enthesitis Index ≤ 1 (assesses the presence or absence of enthesitis at 3 bilateral sites, with an overall score range from 0 to 6)

    Time frame: At Week 16

  2. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response

    Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: At Week 16

  3. Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response

    Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR70 response criteria: 1. ≥ 70% improvement in 68-tender joint count; 2. ≥ 70% improvement in 66-swollen joint count; and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * Patient global assessment of disease activity * Patient assessment of pain * Health Assessment Questionnaire - Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP).

    Time frame: At Week 16

  4. Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response (in the subset of participants with a PsO BSA ≥ 3% at Baseline)

    PASI is a composite score based on the percentage of the body surface area (BSA) affected by psoriasis and the intensity of erythema (reddening), induration (thickening or hardening of the skin), and desquamation (peeling of the skin) of lesions assessed at 4 anatomic sites (head, upper extremities, trunk, and lower extremities). At each location, the percentage of BSA involvement is assigned a score from 0 (no involvement) to 6 (90% to 100% involvement), and erythema, induration, and desquamation are scored on a scale from 0 (no symptoms) to 4 (very marked). The PASI score ranges from 0 (no psoriasis) to 72 (very severe psoriasis). A PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from Baseline in PASI score, and was assessed in participants with Baseline psoriasis BSA involvement ≥ 3%.

    Time frame: At Week 16

07

Study locations

35 of 41 sites recruiting
  • Newport Huntington Medical Group /ID# 272764
    Huntington Beach, California 92648-5994, United States
    Recruiting
    • Site Coordinator · Contact714-923-7112
  • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
    Avon Park, Florida 33825, United States
    Recruiting
    • Site Coordinator · Contact863-314-8555
  • Clinical Research Of West Florida - Phase I Unit /ID# 273198
    Clearwater, Florida 33765, United States
    Recruiting
  • HMD Research LLC /ID# 273086
    Orlando, Florida 32819, United States
    Recruiting
  • West Broward Rheumatology Associates /ID# 272892
    Tamarac, Florida 33321, United States
    Recruiting
  • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
    Tampa, Florida 33606, United States
    Recruiting
    • Site Coordinator · Contact(813) 870-1292
  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469
    Chicago, Illinois 60611, United States
    Recruiting
  • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879
    Skokie, Illinois 60076, United States
    Completed

    Not enrolling at this site — choose another above.

  • Willow Rheumatology and Wellness /ID# 277354
    Willowbrook, Illinois 60527, United States
    Recruiting
  • Klein & Associates /ID# 272829
    Cumberland, Maryland 21502, United States
    Completed

    Not enrolling at this site — choose another above.

  • Dartmouth-Hitchcock Medical Center /ID# 272702
    Lebanon, New Hampshire 03756, United States
    Recruiting
    • Site Coordinator · Contact603-650-4717
  • Paramount Medical Research and Consulting /ID# 272757
    Middleburg Heights, Ohio 44130, United States
    Recruiting
  • Altoona Center For Clinical Research /ID# 272593
    Duncansville, Pennsylvania 16635, United States
    Recruiting
    • Site Coordinator · Contact814-296-6108
  • Private Practice - Dr. Ramesh C. Gupta /ID# 272897
    Memphis, Tennessee 38119, United States
    Recruiting
  • Tekton Research - West Gate /ID# 272765
    Austin, Texas 78745, United States
    Recruiting
  • Arthritis and Rheumatology Research Institute - Frisco /ID# 277306
    Frisco, Texas 75035, United States
    Recruiting
  • Accurate Clinical Research - Houston /ID# 272754
    Houston, Texas 77089-6142, United States
    Recruiting
  • Tekton Research, LLC /ID# 272901
    San Antonio, Texas 78251, United States
    Recruiting
  • DM Clinical Research - Tomball /ID# 272760
    Tomball, Texas 77375, United States
    Recruiting
  • Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715
    Sherbrooke, Quebec J1G 2E8, Canada
    Recruiting
  • Centre de Recherche Musculo-Squelettique /ID# 274397
    Trois-Rivières, Quebec G9A 3X2, Canada
    Recruiting
  • Dr. Latha Naik Medical Professional Corporation /ID# 272803
    Saskatoon, Saskatchewan S7H 0P4, Canada
    Recruiting
  • Revmatologie /ID# 272367
    Brno, Brno-mesto 638 00, Czechia
    Recruiting
  • L.K.N. Arthrocentrum /ID# 272366
    Hlučín, Moravian-Silesian Region 748 01, Czechia
    Recruiting
  • Medical Plus Research /ID# 272363
    Uherské Hradiště, 686 01, Czechia
    Recruiting
  • PV Medical Services /ID# 272368
    Zlín, 760 01, Czechia
    Recruiting
  • Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 272771
    Nice, Alpes-Maritimes 06001, France
    Recruiting
  • Infirmerie Protestante De Lyon /ID# 273731
    Caluire-et-Cuire, Auvergne-Rhône-Alpes 69300, France
    Recruiting
  • Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762
    Chambray-lès-Tours, Indre-et-Loire 37170, France
    Recruiting
  • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877
    Orléans, Loiret 45067, France
    Completed

    Not enrolling at this site — choose another above.

  • Chu Bordeaux - Hopital Pellegrin /ID# 273390
    Bordeaux, New Aquitaine 33076, France
    Completed

    Not enrolling at this site — choose another above.

  • Borsod-Abauj-Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktatokorhaz /ID# 272572
    Miskolc, Borsod-Abauj Zemplen county 3529, Hungary
    Recruiting
  • Complex Rendelo Med Zrt. /ID# 272570
    Székesfehérvár, Fejér 8000, Hungary
    Recruiting
  • Vital-Medicina /ID# 272855
    Veszprém, Fejér 8200, Hungary
    Recruiting
  • Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195
    Budapest, 1023, Hungary
    Recruiting
  • Revita Reumatologiai Rendelo (Revita Kft.) /ID# 272857
    Budapest, 1027, Hungary
    Recruiting
  • Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-068, Poland
    Recruiting
  • MCBK S.C. Iwona Czajkowska Anna Podrazka-Szczepaniak /ID# 273305
    Pruszków, Masovian Voivodeship 05-800, Poland
    Recruiting
  • Centrum Medyczne Reuma Park /ID# 273301
    Warsaw, Masovian Voivodeship 02-665, Poland
    Recruiting
  • Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304
    Bialystok, Podlaskie Voivodeship 15-351, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306
    Elblag, Warmian-Masurian Voivodeship 82-300, Poland
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Aug 2029, 52 months after the start.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's planned 52 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Dec 2027 → Aug 2029 and completion Jan 2028 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Mar 7, 2025
StartActual
Apr 11, 2025
Primary completionEst.
Aug 2029was Dec 2027
CompletionEst.
Aug 2029was Jan 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
16 sites added, 12 sites removed. 3 sites changed recruiting status (3 now completed)
Show 3 sites
  • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879 · Skokie, United StatesRecruiting→Completed
  • Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304 · Bialystok, PolandRecruiting→Completed
  • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306 · Elblag, PolandRecruiting→Completed
Show 16 added (7 United States, 3 France, 2 Czechia, 2 Hungary, 1 Canada, 1 Poland)
  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469 · Chicago, United States
  • Willow Rheumatology and Wellness /ID# 277354 · Willowbrook, United States
  • Klein & Associates /ID# 272829 · Cumberland, United States
  • Dartmouth-Hitchcock Medical Center /ID# 272702 · Lebanon, United States
  • Private Practice - Dr. Ramesh C. Gupta /ID# 272897 · Memphis, United States
  • Arthritis and Rheumatology Research Institute - Frisco /ID# 277306 · Frisco, United States
  • DM Clinical Research - Tomball /ID# 272760 · Tomball, United States
  • Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715 · Sherbrooke, Canada
  • Medical Plus Research /ID# 272363 · Uherské Hradiště, Czechia
  • PV Medical Services /ID# 272368 · Zlín, Czechia
  • Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762 · Chambray-lès-Tours, France
  • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877 · Orléans, France
  • Chu Bordeaux - Hopital Pellegrin /ID# 273390 · Bordeaux, France
  • Vital-Medicina /ID# 272855 · Veszprém, Hungary
  • Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195 · Budapest, Hungary
  • Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297 · Bydgoszcz, Poland
Show 12 removed
  • Willow Rheumatology and Wellness, PLLC /ID# 277354 · Willowbrook, United States
  • Klein And Associates /ID# 272829 · Hagerstown, United States
  • Private Practice - Dr. Ramesh C. Gupta I /ID# 272897 · Memphis, United States
  • Dynamed Clinical Research - Tomball /ID# 272760 · Tomball, United States
  • Medical Plus s.r.o. /ID# 272363 · Uherské Hradiště, Czechia
  • PV Medical Services s.r.o. /ID# 272368 · Zlín, Czechia
  • Centre Hospitalier Régional Universitaire De Tours - Hôpital Trousseau /ID# 272762 · Chambray-lès-Tours, France
  • CHU Bordeaux - Hopital Pellegrin /ID# 273390 · Bordeaux, France
  • Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 272877 · Orléans, France
  • Vital-Medicina Kft. /ID# 272855 · Veszprém, Hungary
  • Semmelweis Egyetem Reumatológiai és Immunológiai Klinika /ID# 273195 · Budapest, Hungary
  • Mics Centrum Medyczne Bydgoszcz /ID# 273297 · Bydgoszcz, Poland
Nov 9, 2026
Primary completion
Dec 2027→Aug 2029
Nov 9, 2026
Study completion
Jan 2028→Aug 2029
Nov 9, 2026
Enrollment
120→300
Nov 9, 2026
Eligibility
3 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedParticipant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
  • EditedParticipant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
  • ChangedBefore Participant has active plaque PsO and/or a documented history of plaque PsO.Now Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
Exclusion criteria
  • EditedParticipants with the following active, chronic, or activerecurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
Nov 9, 2026
Interventions
Added Drug: ABBV-701·Drug: ABBV-547. Arm changed Sub-Study 1: Risankizumab Monotherapy→Substudy 1: Risankizumab Monotherapy; Sub-Study 1: Lutikizumab Monotherapy→Substudy 1: Lutikizumab Monotherapy. Arms added: Substudy 2: ABBV-701 Monotherapy·Substudy 2: Risankizumab Monotherapy·Substudy 2: ABBV-701 and Risankizumab Combination Therapy·Substudy 3: ABBV-547 Dose A·Substudy 3: ABBV-547 Dose B·and 1 more
All 6

Substudy 2: ABBV-701 Monotherapy · Substudy 2: Risankizumab Monotherapy · Substudy 2: ABBV-701 and Risankizumab Combination Therapy · Substudy 3: ABBV-547 Dose A · Substudy 3: ABBV-547 Dose B · Substudy 3: ABBV-547 Dose C

Nov 9, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879 · Skokie, United StatesContact removed •••2492
  • Accurate Clinical Research - Houston /ID# 272754 · Houston, United StatesContact removed •••8557
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    16 sites added, 12 sites removed. 3 sites changed recruiting status (3 now completed)
    Show 3 sites
    • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879 · Skokie, United StatesRecruiting→Completed
    • Osteo Medic s.c. Artur Racewicz Jerzy Supronik /ID# 273304 · Bialystok, PolandRecruiting→Completed
    • Centrum Kliniczno-Badawcze J.Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka /ID# 273306 · Elblag, PolandRecruiting→Completed
    Show 16 added (7 United States, 3 France, 2 Czechia, 2 Hungary, 1 Canada, 1 Poland)
    • Northwestern Medicine - Northwestern Memorial Hospital /ID# 275469 · Chicago, United States
    • Willow Rheumatology and Wellness /ID# 277354 · Willowbrook, United States
    • Klein & Associates /ID# 272829 · Cumberland, United States
    • Dartmouth-Hitchcock Medical Center /ID# 272702 · Lebanon, United States
    • Private Practice - Dr. Ramesh C. Gupta /ID# 272897 · Memphis, United States
    • Arthritis and Rheumatology Research Institute - Frisco /ID# 277306 · Frisco, United States
    • DM Clinical Research - Tomball /ID# 272760 · Tomball, United States
    • Centre Hospitalier Universite De Sherbrooke - Hotel-Dieu Hospital /ID# 273715 · Sherbrooke, Canada
    • Medical Plus Research /ID# 272363 · Uherské Hradiště, Czechia
    • PV Medical Services /ID# 272368 · Zlín, Czechia
    • Centre Hospitalier Regional Universitaire De Tours - Hopital Trousseau /ID# 272762 · Chambray-lès-Tours, France
    • Centre Hospitalier Regional d Orleans - Hopital de la Source /ID# 272877 · Orléans, France
    • Chu Bordeaux - Hopital Pellegrin /ID# 273390 · Bordeaux, France
    • Vital-Medicina /ID# 272855 · Veszprém, Hungary
    • Semmelweis Egyetem Reumatologiai es Immunologiai Klinika /ID# 273195 · Budapest, Hungary
    • Medicover Integrated Clinical Services - Bydgoszcz (SMO/Network/Consortium) /ID# 273297 · Bydgoszcz, Poland
    Show 12 removed
    • Willow Rheumatology and Wellness, PLLC /ID# 277354 · Willowbrook, United States
    • Klein And Associates /ID# 272829 · Hagerstown, United States
    • Private Practice - Dr. Ramesh C. Gupta I /ID# 272897 · Memphis, United States
    • Dynamed Clinical Research - Tomball /ID# 272760 · Tomball, United States
    • Medical Plus s.r.o. /ID# 272363 · Uherské Hradiště, Czechia
    • PV Medical Services s.r.o. /ID# 272368 · Zlín, Czechia
    • Centre Hospitalier Régional Universitaire De Tours - Hôpital Trousseau /ID# 272762 · Chambray-lès-Tours, France
    • CHU Bordeaux - Hopital Pellegrin /ID# 273390 · Bordeaux, France
    • Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 272877 · Orléans, France
    • Vital-Medicina Kft. /ID# 272855 · Veszprém, Hungary
    • Semmelweis Egyetem Reumatológiai és Immunológiai Klinika /ID# 273195 · Budapest, Hungary
    • Mics Centrum Medyczne Bydgoszcz /ID# 273297 · Bydgoszcz, Poland
    Primary completion Dec 2027→Aug 2029
    Study completion Jan 2028→Aug 2029
    Enrollment 120→300
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
    • EditedParticipant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
    • ChangedBefore Participant has active plaque PsO and/or a documented history of plaque PsO.Now Participant has active plaque PsO, with at least one psoriatic plaque of >= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
    Exclusion criteria
    • EditedParticipants with the following active, chronic, or activerecurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
    Interventions Added Drug: ABBV-701·Drug: ABBV-547. Arm changed Sub-Study 1: Risankizumab Monotherapy→Substudy 1: Risankizumab Monotherapy; Sub-Study 1: Lutikizumab Monotherapy→Substudy 1: Lutikizumab Monotherapy. Arms added: Substudy 2: ABBV-701 Monotherapy·Substudy 2: Risankizumab Monotherapy·Substudy 2: ABBV-701 and Risankizumab Combination Therapy·Substudy 3: ABBV-547 Dose A·Substudy 3: ABBV-547 Dose B·and 1 more
    All 6

    Substudy 2: ABBV-701 Monotherapy · Substudy 2: Risankizumab Monotherapy · Substudy 2: ABBV-701 and Risankizumab Combination Therapy · Substudy 3: ABBV-547 Dose A · Substudy 3: ABBV-547 Dose B · Substudy 3: ABBV-547 Dose C

    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879 · Skokie, United StatesContact removed •••2492
    • Accurate Clinical Research - Houston /ID# 272754 · Houston, United StatesContact removed •••8557
    + 4 other changes: identifiers, verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06865105
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 7, 2025
Start date
Apr 11, 2025
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Nov 9, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lutikizumab · Risankizumab · ABBV-701

Start the discussion